A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab inCombination with Platinum-based Chemotherapy for the First-line Treatment of Patients with MetastaticSquamous Non-small Cell Lung Cancer...

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1st Line treatment in participants with squamous metastatic Non-Small Cell Lung Cancer and whose tumors express PD-L1 (TC ≥ 1%).

For more information please visit https://clinicaltrials.gov/study/NCT06692738

Interested in Volunteering for the Study?

If you would like more information about this study, please call us at 318-212-8671 .